Coelho Rogerio Vivaldi - 02 Jul 2026 Form 4 Insider Report for Crinetics Pharmaceuticals, Inc. (CRNX)

Reporting relationship: Director
Issuer ticker: CRNX
Reported as of: 02 Jul 2026
Net transaction value: -$120,000
SEC form: 4
Accepted by SEC: 07 Jul 2026, 16:30:37 UTC
Prior SEC filing: 22 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Tobin Schilke, as attorney-in-fact

Key filing fact

Coelho Rogerio Vivaldi filed Form 4 for Crinetics Pharmaceuticals, Inc. (CRNX) on 07 Jul 2026.

Key facts

This page summarizes Coelho Rogerio Vivaldi's Form 4 filing for Crinetics Pharmaceuticals, Inc. (CRNX).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 07 Jul 2026, 16:30.

Change

Previous filing in this sequence was filed on 22 Jun 2026.
Current net transaction value: -$120,000.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001610381 Primary reporting owner

Vivaldi Coelho Rogerio

Relationship: Director
Address: C/O CRINETICS PHARMACEUTICALS, INC., 6055 LUSK BOULEVARD, SAN DIEGO
Signature: /s/ Tobin Schilke, as attorney-in-fact
Signature date: 07 Jul 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CRNX transaction

Common Stock

Sale

Transaction value: $120,000
Shares: -3,000
Change %: -13%
Price: $40.00
Shares after: 19,225
Date: 02 Jul 2026
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 2 footnotes

Footnote F1

The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2025.

Footnote F2

The common stock was sold by the Reporting Person in open market transactions on the transaction date, with a sale price of $40.00 per share.